Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Omada Health, Inc. (OMDA)

Omada Health Q2 revenue rises 43% to $88 million; raises 2026 revenue outlook

Positive Impact 4 of 5 earnings Written later

Omada Health reported second-quarter 2026 revenue of $88 million, up from $61 million a year earlier, and net income of $5 million versus a net loss of $5 million in Q2 2025. The company raised its full-year 2026 revenue and adjusted EBITDA ranges and said co-founder Sean Duffy will move to Executive Chair while President Wei-Li Shao becomes CEO on January 1, 2027.

Key points

  • Q2 2026 revenue of $88 million, up 43% from $61 million in Q2 2025; gross margin of 73% versus 66%
  • Net income of $5 million in Q2 2026 compared with a net loss of $5 million in Q2 2025; adjusted EBITDA of $11 million
  • 2026 revenue outlook raised to $334 million to $340 million from $322 million to $330 million; adjusted EBITDA outlook raised to $21 million to $27 million from $14 million to $20 million
  • Wei-Li Shao to succeed Sean Duffy as CEO effective January 1, 2027; Jeryl Hilleman to become Lead Independent Director

The filing

CompanyOmada Health, Inc. (OMDA)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:02 PM ET
Accession number0001628280-26-054266

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.